BioSpace News Archive

Business

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc. (Nasdaq: SPRB) today reported financial results for the year ended December 31, 2023 and provided corporate updates.

March 13, 2024
·
10 min read
Pharm Country

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, announced the closing of its previously announced private placement.

March 13, 2024
·
5 min read
Business

KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2023.

March 13, 2024
·
20 min read
Lone Star Bio

Corgan Receives Grant from American Society of Interior Designers Foundation to Study Design for Educators with Disabilities

Global architecture firm Corgan has been awarded a $30,000 research grant from the American Society of Interior Designers (ASID) Foundation to study the experiences of teachers with disabilities — a diverse community with limited representation in existing research.

March 13, 2024
·
4 min read
FDA

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis (PFIC).

March 13, 2024
·
9 min read
Deals

Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System

IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, announced today that Novartis has exercised its option to acquire all of the outstanding capital stock of IFM Due, a subsidiary company of IFM.

March 13, 2024
·
3 min read
Business

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence Therapeutics plc today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights.

March 13, 2024
·
10 min read
Pharm Country

Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution

Agile Therapeutics, Inc., a women’s healthcare company, announced that it has paid-off the remainder of its debt facility with Perceptive Advisors.

March 13, 2024
·
3 min read
BioMidwest

Vanqua Bio to Present at the Stifel 2024 CNS Days Conference

Vanqua Bio announced today that the company will participate in the Stifel 2024 CNS Days Conference, which is being held virtually March 19-20.

March 13, 2024
·
1 min read
Drug Development

Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)

Atsena Therapeutics announced dosing has been initiated in the second cohort of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis.

March 13, 2024
·
3 min read